Samsung Biologics Moves Into Peptide Manufacturing

Company Samsung Biologics Event Type M&A / Tender Offer Modality Peptide API Manufacturing (CDMO) Platform PolyPeptide Group (Acquisition Target) Indication Cross-Therapeutic (GLP-1/Metabolic, Diabetes, Oncology, Rare Disease, Endocrinology) Summary Samsung Biologics launched an all-cash tender offer for PolyPeptide Group at CHF 44.31 per share, implying an…